LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

LLY

972.66

-2.04%↓

JNJ

222.08

-0.94%↓

ABBV

202.41

-1.46%↓

UNH

368.41

+0.16%↑

AZN

182.35

-1.44%↓

Home・Akcijų sąrašas・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

3.94 -5.06

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.86

Max

4.13

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-12M -27M
Pardavimai	-5.3M 663K
P/E Sektoriaus vid.	22.5 49.8
Pelno marža	-3,998.492
Darbuotojai	69
EBITDA	-13M -27M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+230.99% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-234M 910M
Ankstesnė atidarymo kaina	9
Ankstesnė uždarymo kaina	3.94

Naujienos nuotaikos

By Acuity

50%

187 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

0.7658 / N/A Palaikymas ir pasipriešinimas

CytomX Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-06 23:41; UTC

Uždarbis

Arm Holdings Lacks Supply to Meet Roaring Demand for New Chips -- Update

2026-05-06 21:40; UTC

Uždarbis

Nutrien Logs Higher Profit, Sales Growth in 1Q

2026-05-06 23:47; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-05-06 23:34; UTC

Rinkos pokalbiai

Gold Prices Steady, Supported by Lower U.S. Treasury Yields -- Market Talk

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net Profit Beat FactSet-Compiled Consensus

2026-05-06 23:13; UTC

Uždarbis

Kakao 1Q Net KRW226.84B Vs. Net KRW200.33B >035720.SE

2026-05-06 23:12; UTC

Uždarbis

Kakao 1Q Oper Pft KRW211.40B Vs. Pft KRW105.40B >035720.SE

2026-05-06 23:11; UTC

Uždarbis

Kakao 1Q Rev KRW1.942T Vs. KRW1.864T >035720.SE

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Loan Growth Outlook for 2026 >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Total Credit Costs at 25-30 Basis Points >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: Low Single-Digit Operating Cost Growth Outlook for 2026>U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: 2026 Outlook for Full-Year NIM of 1.75%-1.80% >U11.SG

2026-05-06 23:11; UTC

Uždarbis

United Overseas Bank's CEO: High Single-Digit Fee Growth Outlook for 2026 >U11.SG

2026-05-06 23:07; UTC

Uždarbis

United Overseas Bank: 1Q Net Profit Decline Reflects Softer Operating Environment >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Fee Income S$637M Vs. S$694M >U11.SG

2026-05-06 23:06; UTC

Uždarbis

United Overseas Bank 1Q Net Interest Income S$2.32B Vs. S$2.41B >U11.SG

2026-05-06 23:05; UTC

Uždarbis

United Overseas Bank 1Q Net S$1.44B Vs. Net S$1.49B >U11.SG

2026-05-06 23:04; UTC

Uždarbis

United Overseas Bank 1Q Total Income S$3.42B Vs. S$3.66B >U11.SG

2026-05-06 22:50; UTC

Uždarbis

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

2026-05-06 22:25; UTC

Rinkos pokalbiai

Canada's Public Finances on Sustainable Path, BOC's Macklem Says -- Market Talk

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q Adj EPS C$0.08 >TKO.LN

2026-05-06 22:11; UTC

Uždarbis

Taseko Mines Ltd. 1Q EPS C$0.05 >TKO.LN

2026-05-06 22:05; UTC

Rinkos pokalbiai

Updated Govt Fiscal Plan Won't Have Sizable Impact on BOC Outlook -- Market Talk

2026-05-06 21:58; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:47; UTC

Rinkos pokalbiai

Uždarbis

Costco Posts 13% Sales Growth in April -- Market Talk

2026-05-06 21:46; UTC

Uždarbis

IonQ Doubles Down on Nvidia Comparison. Why the Stock Is Falling After Blowout Earnings. -- Barrons.com

2026-05-06 21:40; UTC

Uždarbis

Arm Stock Takes Wild Ride After Earnings. Demand Might Be Too Strong to Meet. -- Barrons.com

2026-05-06 21:35; UTC

Rinkos pokalbiai

BOC's Macklem Defends Warning About Rate Hikes to Fight Inflation -- Market Talk

2026-05-06 21:32; UTC

Karštos akcijos

Stocks to Watch Wednesday Recap: Advanced Micro Devices, Flutter, Disney, Uber -- WSJ

2026-05-06 21:29; UTC

Uždarbis

Fastly Stock Tumbles. An Earnings Beat Pauses a Monster Rally. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

CytomX Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

230.99% į viršų

12 mėnesių prognozė

Vidutinis 13.67 USD 230.99%

Aukščiausias 17 USD

Žemiausias 11 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CytomX Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių CytomX Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.7658 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Rinkos nuotaikos

By Acuity

187 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.